Skip to main content
. Author manuscript; available in PMC: 2013 May 16.
Published in final edited form as: Breast Cancer Res Treat. 2010 Sep 29;124(3):723–732. doi: 10.1007/s10549-010-1181-8

Table 2.

Pathologic response rate for breast cancer subtypes based on HR and Her2 status

Subtype Total Proportion of patients who
received trastuzumab		 Proportion of patients with
pathologic response (pCR + pPR)
Entire cohort (n = 105)
 HR positive 57 5/57 (2 with pathologic response) 10/57 (18%)
 HR negative 48 3/48 (3 with pathologic response) 26/48 (54%)
Cohort with Her2 status available (n = 85)
 HR positive/Her2 negative 34 N/A 6/34 (17.7%)
 HR positive/Her2 positive 13 5/13 (2 with pathologic response) 3/13 (23.1%)
 HR negative/Her2 positive 14 3/14 (3 with pathologic response) 7/14 (50.0%)
 HR negative/Her2 negative (triple negative) 24 N/A 13/24 (54.2%)

HR hormone receptor, Her2 human epidermal growth factor receptor, pCR pathologic complete response, pPR pathologic partial response